A biotech firm has made a major breakthrough in the treatment of cat allergies.
Circassia, based at the Oxford Science Park, has received positive results from a trial of its ToleroMune treatment which showed adverse skin reactions were reduced by up to 40 per cent from a single dose.
Chief executive Steve Harris said: "These results are extremely encouraging, both for Circassia and the huge number of people who suffer from allergies.
"Current treatment options address the symptoms only or require repeated administrations over many months under specialist supervision because of the potential for serious and even life-threatening side effects, which is a particularly important issue for cat allergy therapies.
"Achieving a marked reduction in allergic responses after just a single dose is remarkable, and we aim to build on this by testing short treatments of several doses in future trials."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here